SG10202108219QA - Prophylactic and/or therapeutic agent of infectious disease or inflammatory disease - Google Patents
Prophylactic and/or therapeutic agent of infectious disease or inflammatory diseaseInfo
- Publication number
- SG10202108219QA SG10202108219QA SG10202108219QA SG10202108219QA SG10202108219QA SG 10202108219Q A SG10202108219Q A SG 10202108219QA SG 10202108219Q A SG10202108219Q A SG 10202108219QA SG 10202108219Q A SG10202108219Q A SG 10202108219QA SG 10202108219Q A SG10202108219Q A SG 10202108219QA
- Authority
- SG
- Singapore
- Prior art keywords
- disease
- prophylactic
- therapeutic agent
- inflammatory disease
- infectious disease
- Prior art date
Links
- 208000035473 Communicable disease Diseases 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 208000015181 infectious disease Diseases 0.000 title 1
- 208000027866 inflammatory disease Diseases 0.000 title 1
- 230000000069 prophylactic effect Effects 0.000 title 1
- 229940124597 therapeutic agent Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
- G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0337—Animal models for infectious diseases
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0368—Animal model for inflammation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/775—Apolipopeptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pathology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Diabetes (AREA)
- Environmental Sciences (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017013486 | 2017-01-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10202108219QA true SG10202108219QA (en) | 2021-08-30 |
Family
ID=62978497
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10202108219QA SG10202108219QA (en) | 2017-01-27 | 2018-01-26 | Prophylactic and/or therapeutic agent of infectious disease or inflammatory disease |
SG11201906968YA SG11201906968YA (en) | 2017-01-27 | 2018-01-26 | Prophylactic and/or therapeutic agent of infectious disease or inflammatory disease |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201906968YA SG11201906968YA (en) | 2017-01-27 | 2018-01-26 | Prophylactic and/or therapeutic agent of infectious disease or inflammatory disease |
Country Status (9)
Country | Link |
---|---|
US (2) | US20190367600A1 (en) |
EP (2) | EP3581204A4 (en) |
JP (1) | JP7126658B2 (en) |
KR (1) | KR102581165B1 (en) |
CN (1) | CN110267680B (en) |
AU (1) | AU2018213716A1 (en) |
CA (1) | CA3051826A1 (en) |
SG (2) | SG10202108219QA (en) |
WO (1) | WO2018139608A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2020376350A1 (en) * | 2019-10-30 | 2022-05-26 | National University Corporation Okayama University | Prophylactic and/or therapeutic agent for inflammatory pulmonary disease |
WO2024004580A1 (en) * | 2022-06-30 | 2024-01-04 | 国立大学法人千葉大学 | Method for testing disease progression toward vasculitis or testing risk of covid-19 becoming severe, testing kit, companion diagnostic agent, and testing marker |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US164290A (en) | 1875-06-08 | Improvement in bedsteads | ||
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
CA2078539C (en) | 1991-09-18 | 2005-08-02 | Kenya Shitara | Process for producing humanized chimera antibody |
JP2000014383A (en) | 1998-07-03 | 2000-01-18 | Igaku Seibutsugaku Kenkyusho:Kk | Humanized antibody |
FR2801407B1 (en) | 1999-11-22 | 2002-04-12 | Roger Felix Sejalon | CONTINUOUSLY TRACABLE INVIOLABLE LABEL BRACELET |
JP2004081199A (en) | 2002-06-25 | 2004-03-18 | Sekisui Chem Co Ltd | Method for producing recombinant antibody |
US9028822B2 (en) * | 2002-06-28 | 2015-05-12 | Domantis Limited | Antagonists against TNFR1 and methods of use therefor |
JP3965147B2 (en) | 2003-11-04 | 2007-08-29 | ヤンマー株式会社 | Claw shaft attachment / detachment structure of rotary tiller |
EP2306192B1 (en) * | 2003-12-05 | 2015-10-14 | The Cleveland Clinic Foundation | Risk Markers For Cardiovascular Disease |
GB0701626D0 (en) * | 2007-01-22 | 2007-03-07 | Cambridge Entpr Ltd | Methods and biomarkers for diagnosing and monitoring psychotic disorders |
WO2009044723A1 (en) * | 2007-10-04 | 2009-04-09 | Biomarker Science Co., Ltd. | Method for prediction of effect of interferon therapy and kit for prediction |
GB0720976D0 (en) * | 2007-10-26 | 2007-12-05 | Medical Res Council | Treatment of inflammatory disease |
US8225183B2 (en) | 2008-09-30 | 2012-07-17 | Lsi Corporation | Methods and apparatus for selective data retention decoding in a hard disk drive |
US9435813B2 (en) * | 2010-05-11 | 2016-09-06 | The General Hospital Corporation | Biomarkers of hemorrhagic shock |
US9244079B2 (en) | 2010-09-22 | 2016-01-26 | National University Corporation Chiba University | Testing method and testing reagent for angiitis |
US10196457B2 (en) * | 2011-12-19 | 2019-02-05 | National University Corporation Chiba University | Artificial immunoglobulin fragment composition |
US10208131B2 (en) | 2011-12-19 | 2019-02-19 | National University Corporation Chiba University | Artificially produced polyclonal immunoglobulin preparation |
US20160245815A1 (en) * | 2013-10-01 | 2016-08-25 | Toray Industries, Inc. | Method for detecting pancreatic tumor, antibodies, and kit for the detection of pancreatic tumor |
JP5685672B1 (en) | 2014-07-10 | 2015-03-18 | 株式会社山岡製作所 | Resin molding method |
DK3252474T3 (en) * | 2015-01-26 | 2020-11-09 | Toray Industries | PROCEDURE AND KIT FOR DETECTING BILEWAY CANCER |
JP6670129B2 (en) | 2015-02-27 | 2020-03-18 | 国立大学法人千葉大学 | Artificial immunoglobulin fragment composition |
DK3267197T3 (en) * | 2015-03-02 | 2020-10-12 | Toray Industries | METHOD AND KIT FOR THE DETECTION OF PANCREATIC DYSFUNCTION |
US9895848B2 (en) | 2015-04-22 | 2018-02-20 | The Boeing Company | Systems and tooling for manufacturing composite parts and related methods |
JP6453199B2 (en) | 2015-10-16 | 2019-01-16 | 光洋機械工業株式会社 | Centerless grinding machine |
-
2018
- 2018-01-26 EP EP18744092.0A patent/EP3581204A4/en not_active Withdrawn
- 2018-01-26 SG SG10202108219QA patent/SG10202108219QA/en unknown
- 2018-01-26 CN CN201880008834.3A patent/CN110267680B/en active Active
- 2018-01-26 WO PCT/JP2018/002576 patent/WO2018139608A1/en active Search and Examination
- 2018-01-26 KR KR1020197024894A patent/KR102581165B1/en active IP Right Grant
- 2018-01-26 EP EP23201475.3A patent/EP4317431A3/en active Pending
- 2018-01-26 AU AU2018213716A patent/AU2018213716A1/en active Pending
- 2018-01-26 CA CA3051826A patent/CA3051826A1/en active Pending
- 2018-01-26 JP JP2018564666A patent/JP7126658B2/en active Active
- 2018-01-26 US US16/481,241 patent/US20190367600A1/en not_active Abandoned
- 2018-01-26 SG SG11201906968YA patent/SG11201906968YA/en unknown
-
2022
- 2022-03-21 US US17/655,687 patent/US20220213180A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CA3051826A1 (en) | 2018-08-02 |
US20220213180A1 (en) | 2022-07-07 |
KR20190108152A (en) | 2019-09-23 |
EP3581204A4 (en) | 2020-12-16 |
KR102581165B1 (en) | 2023-09-21 |
WO2018139608A1 (en) | 2018-08-02 |
JPWO2018139608A1 (en) | 2020-01-09 |
JP7126658B2 (en) | 2022-08-29 |
US20190367600A1 (en) | 2019-12-05 |
EP3581204A1 (en) | 2019-12-18 |
EP4317431A3 (en) | 2024-05-22 |
AU2018213716A1 (en) | 2019-08-15 |
SG11201906968YA (en) | 2019-08-27 |
EP4317431A2 (en) | 2024-02-07 |
CN110267680B (en) | 2023-12-19 |
CN110267680A (en) | 2019-09-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB2582482B (en) | CASZ compositions and methods of use | |
EP3878348C0 (en) | Medical devices and methods of use | |
GB2582100B (en) | CAS12C Compositions and methods of use | |
IL273959A (en) | Methods and compositions for the treatment of rare diseases | |
EP3503903A4 (en) | Ascaroside treatment of autoimmune and inflammatory diseases | |
HK1251265A1 (en) | Diagnosis and treatment of infectious disease | |
IL247368A0 (en) | Diagnostic and therapeutic uses of exosomes | |
ZA201906169B (en) | Synthekine compositions and methods of use | |
SG11201912185XA (en) | Three dimensional tissue compositions and methods of use | |
IL285928A (en) | Fulvestrant formulations and methods of their use | |
FI3380525T3 (en) | Pharmaceutical formulations and methods of use thereof | |
EP3473259A4 (en) | Trophic factor release agent and inflammatory disease treatment agent | |
SG10202108219QA (en) | Prophylactic and/or therapeutic agent of infectious disease or inflammatory disease | |
IL274433A (en) | Fulvestrant formulations and methods of their use | |
ZA201906964B (en) | Prevention and/or treatment of inflammatory skin disease | |
GB2615479B (en) | Therapeutic and prophylactic use of microoganisms | |
SG11201704430SA (en) | Preventive and/or therapeutic agent of immune disease | |
GB201522329D0 (en) | Use of adjuvants for the prevention and/or treatment of autoimmune diseases | |
EP3648777A4 (en) | Exosomes and methods of use thereof | |
EP3536382A4 (en) | Prophylactic or therapeutic agent for inflammatory skin disease | |
IL272604A (en) | Methods and compositions for treatment of inflammatory bowel disease | |
EP3272349A4 (en) | Therapeutic and/or prophylactic agent for lewy body diseases | |
EP3616687C0 (en) | Preparation for the treatment and/or prophylaxis of inflammatory infectious diseases | |
SG11202002316PA (en) | Prophylactic and/or therapeutic agent for diseases involving ido expression | |
GB201718856D0 (en) | Medicinal compositions for the treatment of inflammatory conditions and autoimmune diseases |